A Study of Inhaled AZD8630 in Adolescents With Asthma
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
10actual
Sites
9
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-11 | actual | When the study began enrolling |
| Primary completion | 2025-09-19 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-19 | actual | The whole study's end, after follow-up |
| First posted | 2025-07-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Asthma
Interventions
- Drug: AZD8630
- Device: Dry powder inhaler
Primary outcomes
what the primary-completion date above is the date OFArea under the serum concentration-time curve from time zero to 24 hours (AUC0-24)
measured Up to Day 9
Maximum observed drug concentration (Cmax)
measured Up to Day 9
Time to reach peak or maximum observed concentration (Tmax)
measured Up to Day 9
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed